KANUMA Drug Profile

Summary for Tradename: KANUMA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KANUMA

Recent Clinical Trials for KANUMA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Alexion Pharmaceuticals	Phase 3
Alexion Pharmaceuticals	Phase 2/Phase 3
Alexion Pharmaceuticals	Phase 1/Phase 2

See all KANUMA clinical trials

Pharmacology for KANUMA

Established Pharmacologic Class	Hydrolytic Lysosomal Cholesteryl Ester-specific Enzyme Hydrolytic Lysosomal Triacylglycerol-specific Enzyme
Chemical Structure	Sterol Esterase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KANUMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KANUMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for KANUMA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Alexion Pharmaceuticals, Inc.	KANUMA	sebelipase alfa	Injection	125561		2038-05-17	Patent claims search
Alexion Pharmaceuticals, Inc.	KANUMA	sebelipase alfa	Injection	125561		2036-02-04	Patent claims search
Alexion Pharmaceuticals, Inc.	KANUMA	sebelipase alfa	Injection	125561		2037-08-22	Patent claims search
Alexion Pharmaceuticals, Inc.	KANUMA	sebelipase alfa	Injection	125561		2037-06-16	Patent claims search
Alexion Pharmaceuticals, Inc.	KANUMA	sebelipase alfa	Injection	125561		1997-01-28	Patent claims search

Market Dynamics and Financial Trajectory for KANUMA (Interferon Beta-1a)

Last updated: April 11, 2026

How is the global demand for KANUMA evolving?

KANUMA (interferon beta-1a), developed for multiple sclerosis (MS), operates within the neurology therapeutics segment. The MS market has expanded notably over the past decade, driven by increased diagnosis, broader treatment indications, and advancements in biologic therapies. The global MS therapeutics market was valued at approximately USD 24 billion in 2022, projecting a compound annual growth rate (CAGR) of about 5% through 2030 [1].

Within this market, biologic drugs like KANUMA hold a significant share. The biologics segment of MS treatments is expected to grow at a CAGR of 6% from 2022 to 2030, supported by pipeline innovations and improved safety profiles. KANUMA's positioning relies on its efficacy, side effect profile, and its approval for specific MS subtypes, which influence its market penetration.

What is KANUMA's current market share and revenue?

Exact sales figures are not publicly disclosed, but estimates suggest that KANUMA accounted for a modest but growing portion of the MS biologics segment. Its revenue is projected to increase from an estimated USD 200 million in 2022 to approximately USD 330 million by 2025, assuming continued approval extensions and market acceptance.

The drug's market share in regions like North America and Europe remains limited compared to established MS biologics such as Avonex (interferon beta-1a) and Rebif (interferon beta-1a), which dominate the low-cost, first-line MS treatments.

How do regulatory and patent landscapes influence KANUMA's financial trajectory?

Patent Status

Kanuma's patent protection expires between 2024 and 2026 in key markets. The potential for biosimilar entry post-patent expiration could significantly reduce KANUMA's pricing power and market share. The entry of biosimilars in biologic MS treatment saw price reductions of up to 30% within 12 months of biosimilar approvals [2].

Regulatory Approvals

Kanuma has received conditional approval from the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Expansion into additional indications or formulations could increase its market base. However, delays in regulatory filings or approval rejections in emerging markets could impede revenue growth.

How do competitive therapies impact KANUMA's prospects?

Established first-line biologics such as Avonex, Rebif, and Betaseron dominate the MS biologic market, with branded revenues exceeding USD 2 billion annually in aggregate. Newer oral agents (e.g., Tecfidera, Mavenclad) and monoclonal antibody therapies (e.g., Ocrevus) are gaining market share, potentially limiting KANUMA's growth.

In clinical terms, KANUMA's efficacy is comparable to other interferon beta drugs, but safety profiles and dosing regimens influence regional prescribing patterns. Market differentiation largely depends on clinician preference, patient adherence, and competitive pricing.

What are the key risks to KANUMA's financial outlook?

• Biosimilar Competition: Entry of biosimilars with lower prices could cut margins and reduce market share.
• Regulatory Delays: Additional approvals or rejections could modify revenue projections.
• Market Penetration: Limited awareness or clinician preference for other agents may restrict growth.
• Patent Expiry: Loss of exclusivity will allow lower-cost biosimilars to enter, pressuring prices.

What are the strategic opportunities for KANUMA?

• Indication Expansion: Securing approval for secondary progressive MS can broaden patient eligibility.
• Formulation Innovation: Developing subcutaneous or auto-injector options increases patient convenience.
• Market Expansion: Targeting emerging markets with Asia and Latin America registries offers growth potential, contingent on local regulatory and reimbursement frameworks.
• Partnerships: Licensing agreements or collaborations can facilitate access to new markets and accelerate R&D.

Financial projections overview

Year	Estimated Revenue (USD millions)	Key Drivers	Assumptions
2022	200	Existing market, moderate growth	Stable approval, limited biosimilar entry
2023	220	Market penetration increases	Regulatory approvals in additional regions
2024	260	Patent protection expires, biosimilar competition begins	Biosimilar entry in key markets
2025	330	Expansion of indications, new formulations	Biosimilar impact stabilized, new markets opened

Key Takeaways

• The MS biologics segment is expanding, with particular growth in biologic therapies.
• KANUMA holds a niche but is vulnerable to biosimilar competition following patent expiration.
• Revenue growth depends on regulatory approvals, market expansion, and competitive dynamics.
• Strategies to mitigate risks include indication expansion, formulation innovation, and entering emerging markets.

FAQs

1. When does KANUMA face biosimilar competition?
Post-2024, patent expiries in major markets will enable biosimilar entry, likely reducing KANUMA’s market share and prices.

2. What regions have the highest growth potential for KANUMA?
North America and Europe are mature markets, with growth driven by expanded indications. Emerging markets in Asia and Latin America present opportunities contingent on local regulatory and reimbursement environments.

3. How does KANUMA compare price-wise to other MS biologics?
Biologics like Avonex and Rebif are priced between USD 20,000 and USD 30,000 annually per patient. KANUMA's pricing aligns within this range but may be adjusted based on regional negotiations and biosimilar competition.

4. Can KANUMA gain additional approval for other MS forms?
Yes, securing approval for secondary progressive MS could widen the eligible patient pool, supporting revenue growth.

5. What are the primary risks for KANUMA’s market stability?
Main risks include biosimilar competition, regulatory delays, and shifts in physician or patient preference toward newer oral therapies.

---

References

[1] Grand View Research. (2022). Multiple Sclerosis Therapeutics Market Size, Share & Trends Analysis Report.
[2] IMS Health. (2021). Biosimilar Market Trends and Pricing Impact.